Oxprenolol

Oxprenolol

Clinical data
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Pregnancy category	AU: C
Routes of administration	oral
ATC code	C07AA02 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	20-70%
Metabolism	Hepatic
Elimination half-life	1-2hours
Excretion	Renal Lactic (In lactiferous females)
Identifiers
IUPAC name (RS)-1-[2-(Allyloxy)phenoxy]-3-(isopropylamino)propan-2-ol
CAS Number	6452-71-7 Y
PubChem CID	4631
DrugBank	DB01580 N
ChemSpider	4470 Y
UNII	519MXN9YZR
KEGG	D08318 Y
ChEMBL	ChEMBL546 Y
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C15H23NO3
Molar mass	265.348
3D model (JSmol)	Interactive image
SMILES O(c1ccccc1OC\C=C)CC(O)CNC(C)C
InChI InChI=1S/C15H23NO3/c1-4-9-18-14-7-5-6-8-15(14)19-11-13(17)10-16-12(2)3/h4-8,12-13,16-17H,1,9-11H2,2-3H3 Y Key:CEMAWMOMDPGJMB-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

WikiDoc Resources for Oxprenolol
Articles
Most recent articles on Oxprenolol Most cited articles on Oxprenolol Review articles on Oxprenolol Articles on Oxprenolol in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Oxprenolol Images of Oxprenolol Photos of Oxprenolol Podcasts & MP3s on Oxprenolol Videos on Oxprenolol
Evidence Based Medicine
Cochrane Collaboration on Oxprenolol Bandolier on Oxprenolol TRIP on Oxprenolol
Clinical Trials
Ongoing Trials on Oxprenolol at Clinical Trials.gov Trial results on Oxprenolol Clinical Trials on Oxprenolol at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Oxprenolol NICE Guidance on Oxprenolol NHS PRODIGY Guidance FDA on Oxprenolol CDC on Oxprenolol
Books
Books on Oxprenolol
News
Oxprenolol in the news Be alerted to news on Oxprenolol News trends on Oxprenolol
Commentary
Blogs on Oxprenolol
Definitions
Definitions of Oxprenolol
Patient Resources / Community
Patient resources on Oxprenolol Discussion groups on Oxprenolol Patient Handouts on Oxprenolol Directions to Hospitals Treating Oxprenolol Risk calculators and risk factors for Oxprenolol
Healthcare Provider Resources
Symptoms of Oxprenolol Causes & Risk Factors for Oxprenolol Diagnostic studies for Oxprenolol Treatment of Oxprenolol
Continuing Medical Education (CME)
CME Programs on Oxprenolol
International
Oxprenolol en Espanol Oxprenolol en Francais
Business
Oxprenolol in the Marketplace Patents on Oxprenolol
Experimental / Informatics
List of terms related to Oxprenolol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Oxprenolol (Trasacor, Trasicor, Coretal, Laracor, Slow-Pren, Captol, Corbeton, Slow-Trasicor, Tevacor, Trasitensin, Trasidex) is a non-selective beta blocker with some intrinsic sympathomimetic activity. It is used for the treatment of angina pectoris, abnormal heart rhythms and high blood pressure.

Oxprenolol is a lipophilic beta blocker which passes the blood–brain barrier more easily than water soluble beta blockers. As such, it is associated with a higher incidence of CNS-related side effects than hydrophilic ligands such as atenolol, sotalol and nadolol.

Oxprenolol is a potent beta blocker and should not be administered to asthmatics under any circumstances due to their low beta levels as a result of depletion due to other asthma medication, and because it can cause irreversible, often fatal, airway failure and inflammation.

Stereochemistry

Oxprenolol is a chiral compound, the beta blocker is used as a racemate, e. g. a 1:1 mixture of (R)-(+)-oxprenolol and (S)-(–)-oxprenolol. Analytical methods (HPLC) for the separation and quantification of (R)-(+)-oxprenolol and (S)-(–)-oxprenolol in urine and in pharmaceutical formulations have been described in the literature.